Importantly, in contrast with competitive AR antagonists, eliminating AR protein with SARD279 was found to be antiproliferative in AR-dependent prostate cancer cell lines and also in castration-resistant prostate cell lines, whether resistance to antiandrogens resulted from increased androgen levels or from the F876L AR mutation that converts antagonists into agonists [23]. The gene discussed is AR; the disease is prostate cancer.